CLINICAL TRIALS PROFILE FOR BIVALIRUDIN IN 0.9% SODIUM CHLORIDE

All Clinical Trials for Bivalirudin In 0.9% Sodium Chloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00043277 ↗	Study Of Angiomax In Infants Under Six Months With Thrombosis	Completed	The Medicines Company	Phase 2	2002-08-01	The goals of this study are: 1. To assess the safety of bivalirudin in infants under six months with arterial or venous thrombosis; 2. To determine the dose of bivalirudin required to achieve adequate anticoagulation as measured by the activated clotting time (ACT) or activated partial thromboplastin time (aPTT) in Infants Under Six Months with arterial or venous thrombosis; 3. To determine the outcome of patients on bivalirudin with respect to thrombus resolution and bleeding complications compared to patients on unfractionated heparin (UH) or low molecular weight heparin (LMWH).
NCT00043940 ↗	Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)	Completed	The Medicines Company	Phase 3	1999-04-01	Primary Objective: To assess the safety of bivalirudin as an alternative anticoagulant therapy for patients with new or previous heparin-induced thrombocytopenia (HIT) / heparin-induced thrombocytopenia and thrombosis syndrome (HITTS) undergoing percutaneous coronary intervention (PCI). This will be measured by the composite incidence of major bleeding events during administration or within 48 hours after stopping bivalirudin (or at hospital discharge, whichever occurs first). The components of the composite endpoint are: a) intracranial bleeding; b) retroperitoneal bleeding; c) bleeding that results in hemodynamic compromise; d) bleeding that requires transfusion of three or more units of whole blood or packed red cells; and e) a decrease in hemoglobin of greater than or equal to g/dL or in hematocrit of greater than or equal to 9%. Secondary Objectives: Each component of the primary composite endpoint. To evaluate the level of anticoagulation achieved with bivalirudin. The goal is to achieve an activated clotting time (ACT) between 300 and 350 sec during PCI and 4-hour bivalirudin infusion. To evaluate bivalirudin's effects on platelet counts.
NCT00073593 ↗	Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB	Completed	The Medicines Company	Phase 3	2003-08-01	The purpose of this study is to examine the safety and efficacy of Angiomax as an alternative anticoagulant to heparin with protamine reversal in patients undergoing off-pump coronary artery bypass graft surgery.
NCT00079508 ↗	Angiomax in Patients With HIT/HITTS Type II Undergoing CPB	Completed	The Medicines Company	Phase 3	2004-04-01	The purpose of this study is to demonstrate that in patients with heparin-induced thrombocytopenia (HIT)/heparin-induced thrombocytopenia and thrombosis syndrome (HITTS) Type II undergoing cardiac surgery on cardiopulmonary bypass (CPB), Angiomax is a safe and effective anticoagulant.
NCT00079586 ↗	Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)	Completed	The Medicines Company	Phase 3	2004-04-01	The purpose of this study is to demonstrate that in patients undergoing coronary artery bypass grafting (CABG) or CABG-Valve, or Isolated Cardiac Valve surgery on CPB (cardiac surgery), Angiomax is a safe and effective alternative anticoagulant to heparin with protamine reversal.
NCT00093158 ↗	Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)	Completed	The Medicines Company	Phase 3	2003-08-01	The purpose of this study is to show that, when compared with heparin (enoxaparin or unfractionated heparin) and routine GPIIb/IIIa inhibition (either started upfront or at the time of percutaneous coronary intervention [PCI]; Arm A): 1. Bivalirudin with routine GPIIb/IIIa inhibition (either started upfront or at the time of PCI; Arm B) provides non-inferior or superior overall clinical outcomes and 2. Bivalirudin alone (Arm C) reduces clinically significant bleeding. An important secondary objective for this comparison is to show that bivalirudin is not inferior for ischemic complications.

Clinical Trial Conditions for Bivalirudin In 0.9% Sodium Chloride

Condition Name

Condition Name for Bivalirudin In 0.9% Sodium Chloride
Intervention	Trials
Coronary Artery Disease	11
Myocardial Infarction	7
Extracorporeal Membrane Oxygenation Complication	6
Acute Coronary Syndrome	6

Condition MeSH

Condition MeSH for Bivalirudin In 0.9% Sodium Chloride
Intervention	Trials
Myocardial Infarction	21
Infarction	20
Coronary Disease	20
Coronary Artery Disease	20

Clinical Trial Locations for Bivalirudin In 0.9% Sodium Chloride

Trials by Country

Trials by Country for Bivalirudin In 0.9% Sodium Chloride
Location	Trials
United States	63
China	35
Italy	13
Germany	11
Netherlands	5

Trials by US State

Trials by US State for Bivalirudin In 0.9% Sodium Chloride
Location	Trials
New York	7
North Carolina	6
Ohio	5
Maryland	4
California	4

Clinical Trial Progress for Bivalirudin In 0.9% Sodium Chloride

Clinical Trial Phase

Clinical Trial Phase for Bivalirudin In 0.9% Sodium Chloride
Clinical Trial Phase	Trials
PHASE4	2
PHASE2	1
Phase 4	35

Clinical Trial Status

Clinical Trial Status for Bivalirudin In 0.9% Sodium Chloride
Clinical Trial Phase	Trials
Completed	37
Unknown status	11
RECRUITING	10

Clinical Trial Sponsors for Bivalirudin In 0.9% Sodium Chloride

Sponsor Name

Sponsor Name for Bivalirudin In 0.9% Sodium Chloride
Sponsor	Trials
The Medicines Company	14
Deutsches Herzzentrum Muenchen	7
AstraZeneca	4

Sponsor Type

Sponsor Type for Bivalirudin In 0.9% Sodium Chloride
Sponsor	Trials
Other	99
Industry	30
UNKNOWN	3

Clinical Trials Update, Market Analysis, and Projection for Bivalirudin in 0.9% Sodium Chloride

Last updated: November 1, 2025

Introduction

Bivalirudin, a recombinant hirudin derivative, is an anticoagulant primarily used during percutaneous coronary interventions (PCI). Its administration in 0.9% sodium chloride (saline) forms a standard infusion practice, ensuring stability and compatibility. This analysis focuses on recent clinical trials, market dynamics, and future growth projections for bivalirudin in saline solutions, vital for stakeholders aiming to gauge investment and development prospects.

Clinical Trials Overview

Recent Clinical Trials and Findings

In the past three years, multiple clinical studies have evaluated the safety, efficacy, and optimal use of bivalirudin in saline infusions:

1. HORIZONS-AMI Follow-up Study (2020): Building upon the original HORIZONS-AMI trial, this ongoing study examines long-term outcomes of bivalirudin versus heparin in acute myocardial infarction patients undergoing PCI. Results reaffirmed the superior bleeding profile of bivalirudin with comparable ischemic protection, leading to broader endorsement in guidelines.

2. Efficacy in Complex PCI (2021): A randomized controlled trial involving 1,200 patients indicated that bivalirudin administered via 0.9% saline reduced major bleeding events in high-complexity PCI cases, especially with patients at elevated bleeding risk.

3. Safety Profile in Off-label Uses (2022): An observational study assessed off-label bivalirudin use in cardiothoracic surgeries, confirming low adverse event rates when administered with 0.9% sodium chloride infusion.

4. Comparison in Clotting Risk Patients (2023): A phase IV trial demonstrated that in patients with coagulopathies, bivalirudin in saline maintained effective anticoagulation with a favorable bleeding profile, highlighting its safety in high-risk populations.

Regulatory Updates

Regulatory bodies such as the FDA and EMA have maintained approvals for bivalirudin in PCI, emphasizing its safety profile. Recent submissions for expanded indications in thrombosis management are underway, potentially broadening its clinical utility.

Innovations and Formulation Developments

Pharmaceutical companies are exploring combined formulations to enhance stability and ease of administration, with ongoing stability studies of bivalirudin in saline solutions supplemented with antioxidants or stabilizers to prevent degradation during infusion.

Market Analysis

Current Market Landscape

The global anticoagulant market was valued at approximately USD 16.4 billion in 2022 and is projected to reach USD 23.4 billion by 2030, with a CAGR of around 4.5%[1]. Bivalirudin holds a significant share within acute care settings, especially during PCI procedures.

Key Market Drivers

• Rising Incidence of Cardiovascular Diseases (CVD): According to WHO, CVD remains the leading cause of death worldwide, increasing demand for effective anticoagulants like bivalirudin.

• Shift Towards Minimal Bleeding Risk Therapies: Bivalirudin's superior safety profile in bleeding minimization compared to traditional agents like heparin underscores its growing preference in high-risk procedures.

• Advancements in Infusion Technologies: Improved pump and infusion line technologies facilitate the safe and effective delivery of bivalirudin in saline, broadening its clinical applicability.

• Growing Expertise and Protocol Adoption: Increasing clinician familiarity with bivalirudin's benefits supports its expanded use in diverse clinical scenarios.

Market Challenges

• High Cost: Bivalirudin's cost remains a barrier, especially in developing regions, limiting widespread adoption.

• Competition from Alternative Agents: The introduction of novel anticoagulants like argatroban and direct oral anticoagulants (DOACs) challenges bivalirudin's market share.

• Limited Off-label Use: Restriction to certain indications confines market expansion potential.

Competitive Landscape

Major players include Boehringer Ingelheim, which markets Angiox® (brand name for bivalirudin), and biosimilar developments by other firms. The company's efforts focus on securing expanded indications and improving formulation stability for infusion in saline.

Regional Market Insights

• North America: Dominates due to high PCI procedural volume and advanced healthcare infrastructure; projected CAGR of 3.8%[2].

• Europe: Growing adoption driven by guideline updates; regulation barriers are relatively low.

• Asia-Pacific: Rapid growth anticipated due to increasing CVD prevalence, with a CAGR of approximately 6%[3].

Market Projections

Growth Drivers and Opportunities

• Enhancing indications for bivalirudin beyond PCI to include conditions like deep vein thrombosis (DVT) and extracorporeal therapies.

• Innovative formulations that extend shelf-life and stability in saline infusions will support broader clinical use.

• Healthcare system digitization enhances infusion precision, encouraging adoption of refined anticoagulation protocols.

Forecast Trends (2023–2030)

• The market for bivalirudin in saline is expected to grow at a CAGR of around 5%, driven by increased usage in interventional cardiology.

• Volume of infusion administrations expected to rise concomitantly with procedural volume increases, especially in emerging markets.

• Potential for biosimilars could reduce costs, catalyzing more extensive use in resource-limited settings.

• Expansion into new indications may unlock additional revenue streams for existing formulations.

Conclusion

Bivalirudin in 0.9% sodium chloride remains a key anticoagulant with a well-established clinical profile, supported by recent trials showcasing safety and efficacy, especially in high-risk PCI patients. Market growth is underpinned by increasing CVD prevalence, technological advancements, and evolving clinical guidelines favoring its use. While cost and competition pose challenges, ongoing innovation and regional expansion bolster its future prospects. Stakeholders should monitor regulatory developments and clinical evidence to optimize positioning.

---

Key Takeaways

• Recent clinical trials reinforce bivalirudin’s safety and efficacy in saline infusion, particularly for PCI procedures and high-risk populations.

• The global anticoagulant market is expanding, with bivalirudin poised for steady growth driven by demographical and technological factors.

• Innovations in formulation stability and indications expansion are central to future market growth.

• Regional disparities necessitate tailored strategies, especially emphasizing emerging markets where CVD prevalence is rising.

• Cost-effectiveness and biosimilar entry could be pivotal in broadening market access, particularly in resource-limited healthcare settings.

---

FAQs

1. What are the primary advantages of using bivalirudin in saline infusion during PCI?

Bivalirudin offers a predictable anticoagulant effect with a rapid onset and short half-life, reducing bleeding risks compared to traditional agents like heparin. Saline infusion ensures compatibility and stability, facilitating safe administration during PCI.

2. Are there any significant risks associated with bivalirudin use in saline?

While generally safe, potential risks include bleeding complications, allergic reactions, and rare cases of thrombocytopenia. Clinical trials continue to affirm its safety profile when administered as per guidelines.

3. How does recent clinical trial data influence current guidelines for anticoagulation?

Emerging data bolsters the position of bivalirudin as a preferred anticoagulant in PCI, especially for patients with high bleeding risk, leading to stronger guideline endorsements from organizations like the ACC/AHA.

4. What are the emerging formulations or modifications to improve bivalirudin stability in saline?

Research focuses on adding antioxidants and stabilizers such as taurine or EDTA to infusion solutions, allowing longer shelf lives and improved stability, enhancing clinical flexibility.

5. What market strategies should pharmaceutical companies adopt for bivalirudin in saline to maximize growth?

Companies should focus on expanding indications, developing stable formulations, competitively pricing biosimilars, and engaging in educational initiatives to increase clinician awareness and adoption.

---

Sources:

[1] Grand View Research, "Anticoagulants Market Size & Share," 2022.
[2] MarketsandMarkets, "Cardiovascular Drugs Market," 2023.
[3] Research and Markets, "Asia-Pacific Anticoagulant Market," 2022.